Chair of pharma firm Roche advocates mandatory Covid-19 vaccination
Christoph Franz said he was in favour of compulsory jabs if vaccination coverage rates were insufficient and if there was a social consensus on the issue.
This content was published on
2 minutes
Keystone-SDA/ac
Português
pt
Presidente de gigante farmacêutica defende vacinação obrigatória
“Solidarity is needed to overcome this crisis together,” Franz said in an interview with the Frankfurter Allgemeine Zeitung. He added that several vaccines had been developed and approved in less than a year. “That normally takes more than five years.”
The 60-year-old wanted production capacities to be built up first. “I am confident that the problems in logistics and distribution of the vaccines will be solved in the next few months,” he told the paper.
The chairman of the Swiss pharma giant was also critical of the focus on prices of vaccines by some countries. He warned that action must be taken more quickly in a pandemic because the damage to the economy is many times greater than cost savings from reducing the price of a vaccine dose.
Roche’s own pill against Covid-19 is still in the second phase of clinical development, Franz said, and has been tested in humans for efficacy and side effects. “We don’t have results yet, but we expect initial data in the next few months and hopefully results from pivotal trials this year.”
On Tuesday, the Swiss government approved the use of Regeneron’s RegN-Cov 2 drug to treat Covid-19 produced by Roche and ordered 3,000 doses of the monoclonal antibody Casirivimab/Imdevimab. The value of the contract is confidential.
Franz has been a board member of Roche since 2011 and chairman since 2014. His profile on the Roche website makes reference to his tendency to say what he thinks.
“He is an unconventional thinker who is not afraid to ask questions that (as he himself says) could turn out to be stupid.”
More
Archived
What do you think of a Covid-19 “vaccine passport” being required for activities such as travelling and going to bars and restaurants?
What do you see as the limits or benefits of this solution?
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
This content was published on
With its big bet on data and digitilisation, Roche has its eye on a new crop of specialists. Now it just needs to woo them.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.